However, the EML expert committee rejected the proposed inclusion of PD1/PD-L1 inhibitors for advanced non-small cell lung cancer (NSCLC) in 2019, 2021, and 2023.14, 15, 16 The committee acknowledged the efficacy and safety of these medicines as first-line monotherapies for advanced NSCLC, which demonstrate substantial benefits according to the European Society of Medical Oncology (ESMO)’s rating of at least 4 on its Magnitude of Clinical Benefit Scale.17 Here, CD274 is linked to non-small cell lung carcinoma.